Beacon Medicare Ltd, one of the leading companies in cancer care in Bangladesh, has stepped up in the world market with its new product Ribotix, the global first generic of Ribociclib. Ribotix is a CDK4/6 inhibitor that is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 [...]
Beacon Medicare Ltd has begun the promotion of Enzalutamide in the global market under the brand name Enzalunix, a non-steroidal anti-androgen medication that is used in the treatment of prostate cancer. Enzalunix is a hormonal therapy which is indicated for metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer [...]
Beacon Pharmaceuticals PLC introduced a noble and selective factor Xa inhibitor drug Rivaroxaban 10mg tablet under brand the name of Rivosis. The company launched the product on August 17, 2021. Rivosis (Rivaroxaban) is indicated for reducing stroke risk in patients of non-valvular atrial fibrillation, reducing recurrence risk of deep vein thrombosis & pulmonary embolism. It [...]
Beacon Pharmaceuticals Limited (BPL) has launched Pandovir 100, a broad-spectrum antiviral medicine, for the treatment of severe Covid-19 cases under the generic of Remdesivir. The BPL launched the generic version of Remdesivir in august in view to provide drug or treatment of Cvid 19 patient in August. Directorate General of Drug Administration (DGDA) considered it [...]
Beacon Medicare Limited (BML) has recently launched a new product under the brand name “Pembroxim”, in injection form, under the generic of Pembrolizumab, to help patients fighting against the infection of certain types of cancer in the world. The medicine will be used in cancer immunotherapy that includes melanoma, head and neck cancer, Hodgkin lymphoma [...]
Beacon Medicare Limited, a number one oncology company in Bangladesh, has launched Pazonix in tablet form under the generic of Pazopanib, an anti-cancer drug, only for export purpose in the world market. Pazonix ( pazopanib) is one of the most advanced & latest drug for the treatment of Renal Cell Carcinoma. This is the global [...]
Beacon Medicare Limited has launched Nivolunix in injection form under the generic of Nivolumab, for treating certain types of cancer. The product was prepared only for export purpose. The medicine will be available in two strengths –40mg/4ml and 100mg/10ml –injections and a vial of the injection. Nivolunix is a humanized antibody that is used in [...]
Beacon Medicare Limited has announced the launching of Nilonix in capsule form under the generic of Nilotinib for the treatment of people, who diagnosed with Philadelphia chromosome positive CML and limatinib resistant Ph+ CML, effectively. The medicine will be available in two strengthens –150mg and 200mg --capsule and the both packets will contain 120 capsules [...]
We are pleased to inform you that Team BML is going to launch Ponatinix Tablet for global market. It will be available in two strengths (45 mg and 15 mg). Each pack of Ponatinix 45 will contains 30 tablets and Ponatinix 15 will contains 60 tablets in HDPE pot. The product is only for global [...]
BEACON introduced another promising multiple Tyrosine kinase inhibitor, Cabozanitib, under the brand name of Cabozanix for global market. Cabozanitibis an anticancer drug for: Renal Cell Carcinoma Metastatic Thyroid Cancer Cabozanix is an oral Capsule preparation which is available in the strengths of 20 mg &80mg. Each pack Cabozanix 20 contains 90 capsules and Cabozanix 80 [...]
Hernix is a kinase inhibitor indicated for: Treatment of adult patients with early stage HER2 overexpressed breast cancer. Hernix can reduce risk of recurrence following Tastuzumab based therapy. Improve disease free survival Significant treatment benefit at 5 years. It is an oral tablet production available in the strength of 40 mg. This product is only [...]
Beacon Medicare Ltd. introduced another block buster drugs Obetix for Cirrhosis Treatment: BEACON introduced a Farnesoid X Receptor agonist , Obeticholic Acid, under the brand name of Obetix for the treatment of Primary Biliary Cirrhosis .. Obetix is a general drugin oral tablet preparation available in the strength of 5 mg. This product is only [...]
BEACON introduced another promising multikinase inhibitor, Lenvatinib, under the brand name of Lenvanix for global market. Lenvatinib is an anticancer drug. It is the First new Front-Line treatment option for Hepatocellular Carcinoma (HCC) approved in Japan in nearly 10 years. First TKI to demonstrating Complete Response (CR) in a phase 3 trial for locally recurrent [...]
Beacon Pharmaceuticals ltd offers Xonimide under the generic of Zonasamide, an antiseizure agent which indicated as Monotherapy in the treatment of partial seizures ,with or without secondary generalization, in adults with newly diagnosed epilepsy Adjunctive therapy in the treatment of partial seizures, with or without secondary generalization, in adults, adolescents, and children aged 6 [...]
Beacon Pharmaceuticals Limited introduces Trihexyphenidyl Hydrochloride under the Brand name Hexinor.Hexinor is now available in syrup.Earlier Beacon has introduced Hexinor in tablet form. Hexinor is used for the treatment of Parkinson disease.
BEACON Pharmaceuticals Limited introduced Eltrombopag under the brand name of ETP for the treatment of thrombocytopenia. Eltrombopag (ETP) is approved by USFDA for the following indications- Thrombocytopenia in adult and pediatric patients of 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP). Thrombocytopenia in patients with chronic hepatitis C. Patients with severe aplastic. ETP [...]
